Functional Outcome of Single Dose of Platlet Rich Plasma Vs Steroid in the Treatment of Chronic Recalcitrant Lateral Epicondylitis

doi:10.5281/zenodo.8248421

International Journal of Medical and Pharmaceutical Research

2023, Volume-4, Issue-4 doi: 10.5281/zenodo.8248421

Original Article

Functional Outcome of Single Dose of Platlet Rich Plasma Vs Steroid in the Treatment of Chronic Recalcitrant Lateral Epicondylitis

Dr. Chandanpreet Kaur

Dr. Neetu Kukar

Dr. Anshul Dahuja

Dr. Radhe Shyam Garg

DOI : 10.5281/zenodo.8248421

Published

Aug. 13, 2023

Abstract

Background: Chronic recalcitrant lateral epicondylitis poses a therapeutic challenge. This study aimed to compare the efficacy of a single dose of Platelet-Rich Plasma (PRP) versus a single dose of steroid in the treatment of this condition.

Methods: A prospective comparative study was conducted on 92 patients with chronic lateral epicondylitis not responding to conservative management. Patients were randomized into PRP (46 subjects) and steroid injection groups (46 subjects) and followed for six months.

Results: The PRP group showed a significant reduction in Visual Analogue Scale (VAS) scores from baseline to six months (6.67 to 0.54; p < 0.001), compared to the steroid group (6.48 to 1.70; p < 0.001). Similarly, the Patient Related Tennis Elbow Evaluation (PRTEE) score in the PRP group improved significantly from baseline to six months (67.24 to 3.82; p < 0.001) versus the steroid group (64.54 to 14.74; p < 0.001).

Conclusion: Our findings suggest that PRP injections are more effective than steroid injections for pain reduction and functional improvement in patients with chronic recalcitrant lateral epicondylitis.

Recommended Articles

Volume-4, Issue-4

Downloads

Download PDF pdf

Download XML

Citations

1716 Views

427 Downloads

Share this article

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.

IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.